JPRN-jRCTs041210023招募中2 期
A phase II study of treatment with neoadjuvant docetaxel, oxaliplatin plus S-1 for advanced esophageal cancer
Kodera Yasuhiro0 个研究点目标入组 45 人开始时间: 2021年5月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •1) Clinical stage II/III/IVa thoracic esophageal cancer
- •2) Histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma or basaloid-squamous cell carcinoma
- •3) Clinical T1-3
- •4) Ages between 20 years and 79 years
- •5) Performance status (PS) 0-1
- •6) Adequate function of vital organs, including bone marrow, liver, and kidney
- •7) Written informed consent
排除标准
- •1) History (within 3 years) of malignancies
- •2) Active infectious disease
- •3) Psychiatric disease
- •4) Continuous systemic steroid therapy
- •5) Allergy of docetaxel, oxaliplatin or S-1
- •6) Persistent intestinal bleeding
- •7) Ineligible for the study at the physician's assessment
研究者
相似试验
已完成
2 期
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer An IKZ-based phase II feasibility studygastric carcinoma100179901001799110017998gastric cancerNL-OMON31603Jeroen Bosch Ziekenhuis50
进行中（未招募）
不适用
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer - DoCCSEUCTR2007-007273-23-NLJeroen Bosch Hospital
进行中（未招募）
不适用
Et fase II forsøg af neoadjuverende behandling med pegyleret liposomal doxorubicin (Caelyx®) og cyklofosfamid +/- trastuzumab med efterfølgende docetaxel til patienter med primær inoperabel og lokoregional avanceret cancer mammae (LABC). - Et videnskabeligt forsøg med kombinations kemoterapi før operation til patienter med brystkræft.EUCTR2008-007951-29-DKHerlev Hospital, Onkologisk Afd. R
进行中（未招募）
1 期
Clinical trial for the evaluation of a new drug (cabozantinib) treatment given before having kidney surgery in patients with kidney cancer that is advanced or has spreadocally Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001201-93-ESFundación ONCOSUR50
进行中（未招募）
不适用
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2009-012853-39-FRCentre Jean Perrin